TRT in Toronto: separating gym-floor claims from clinical fact

What did @gameday_toronto_midtown actually say?

This is a clinic promotional video featuring a doctor answering patient questions. Three distinct claims surface. First, TRT results can appear as fast as "first day, first week" for some men, while TST (testosterone stimulation therapy) "might take a little longer" because it works indirectly. Second, men struggle to find clinics that check testosterone levels. Third, the peptides BPC-157 and Sermorelin are "legal in Canada," with Sermorelin described as "fantastic for building muscle, improving sleep and improving libido."

The video is short, conversational, and leans promotional. None of these claims come with citations, timelines grounded in evidence, or the standard caveats a regulated health professional would typically include. That matters when the audience is men who are already primed to want quick results.

Does the science back this up?

On TRT timelines, the evidence is more nuanced than "first day, first week." Some effects like mood and energy can shift within days, but most measurable outcomes take weeks to months. A systematic review by Saad et al. (2011, Journal of Andrology) mapped onset timelines: libido improvements appear in 3-6 weeks, erectile function at 3-6 months, and body composition changes require at least 3-6 months of consistent therapy. Feeling something quickly is real, but feeling is not the same as physiological change.

On BPC-157 and Sermorelin in Canada, the legal picture is complicated. Health Canada has not approved BPC-157 for human use. Sermorelin was previously approved but was discontinued commercially. Neither claim of straightforward legality holds up cleanly under scrutiny. Sermorelin is available through compounding pharmacies under specific conditions, which is not the same as being broadly "legal" in the way the video implies.

What did they get wrong (or right)?

Credit where it is due: the doctor is correct that individual variability exists in TRT response, and correct that TST methods work more indirectly than direct testosterone injection. Those are defensible positions.

Where this gets problematic is the "first day, first week" framing. It sets an expectation that most men on TRT will not meet in any meaningful clinical sense. Placebo effect is real and documented in testosterone studies. Crawford et al. (2003, Journal of Clinical Endocrinology and Metabolism) found that men in placebo arms of testosterone trials reported symptomatic improvements, which complicates early subjective reports.

The Sermorelin claim is the most overstated. Calling it "fantastic for building muscle, improving sleep and improving libido" without qualification is promotional language, not medical communication. The evidence base for Sermorelin's benefits in non-growth-hormone-deficient adults is limited. Studies like Sigalos and Pastuszak (2018, Sexual Medicine Reviews) note that growth hormone secretagogues show promise but lack robust long-term human trial data.

BPC-157 is even more unsettled. Research is almost entirely animal-based. Claiming it is simply "legal in Canada" without noting its unapproved status for human use is at minimum incomplete.

What should you actually know?

If you are starting TRT, manage your expectations around timing. Most clinicians use a 3-month window before making meaningful adjustments. Feeling better in week one is not a red flag, but it is also not a reliable signal that your levels have stabilized or that the therapy is optimally dosed. Labs typically follow at 6-8 weeks post-initiation.

TST approaches, such as clomiphene citrate or hCG-based protocols, do work indirectly by stimulating endogenous production. The doctor is right that this mechanism differs from exogenous testosterone. Response time data for these approaches is less robust than for direct TRT, but the mechanistic explanation is accurate.

For peptides: in Canada, the regulatory status of any compounded or research peptide is not a simple yes or no. Health Canada regulates drugs under the Food and Drugs Act, and a compound being available through a clinic does not automatically mean it carries a clean legal or safety profile. Anyone considering these treatments should ask specifically about regulatory status, not just availability.